Influence of Everolimus on Cyclosporine Neoral Pharmacokinetics in Chinese de Novo Cardiac Transplant Recipients

2006 ◽  
Vol 38 (7) ◽  
pp. 2032-2034 ◽  
Author(s):  
C.-H. Wang ◽  
N.-K. Chou ◽  
F.-L.L. Wu ◽  
W.-J. Ko ◽  
C.-I. Tsao ◽  
...  
Keyword(s):  
De Novo ◽  
Cardiac Transplant ◽  
Transplant Recipients

EVEROLIMUS IN DE NOVO CARDIAC TRANSPLANT RECIPIENTS: 24-MONTH FOLLOW-UP

2004 ◽  
Vol 78 ◽  
pp. 160
Author(s):  
G Laufer ◽  
M Grimm ◽  
A Haverich ◽  
E M. Tuzcu ◽  
M Vigano ◽  
...  
Keyword(s):  
De Novo ◽  
Cardiac Transplant ◽  
Transplant Recipients

Everolimus in de novo cardiac transplant recipients: 24-month follow-up

2003 ◽  
Vol 22 (1) ◽  
pp. S140-S141 ◽  
Author(s):  
A. Haverich ◽  
E.M. Tuzcu ◽  
M. Viganò ◽  
L. Pulpon ◽  
R.B. Love ◽  
...  
Keyword(s):  
De Novo ◽  
Cardiac Transplant ◽  
Transplant Recipients

Incidence and Treatment of Cancer in Transplant Recipients

1998 ◽  
Vol 8 (2) ◽  
pp. 105-112 ◽  
Author(s):  
Maureen P. Flattery
Keyword(s):  
De Novo ◽  
Solid Organ Transplantation ◽  
Organ Transplant ◽  
Cardiac Transplant ◽  
Solid Organ ◽  
Transplant Recipients ◽  
Organ Transplant Recipients ◽  
Organ Rejection ◽  
Increased Risk ◽  
Actuarial Risk

Solid organ transplantation has been an accepted mode of therapy for the treatment of end-stage organ diseases for many years. Recipients' survival, however, has been hindered by organ rejection and the comorbid diseases that develop as a result of immunosuppressive therapy. In particular, organ transplant recipients have an increased risk of developing cancer de novo after transplantation. Prevalence ranges from 4 to 18% with an average incidence of 6%. Data submitted to the Cincinnati transplant tumor registry have revealed that cancers prevalent in the general population exhibited no increase in rate and may even show a slight decline in the transplant population. Length of survival after transplantation is associated with the likelihood of having cancer; the longer the recipient survives, the greater the chance. The actuarial risk among 124 cardiac transplant recipients was 2.7+/-1.9% at 1 year and 25.6+/-11% at 5 years. This article will review the current literature on the incidence and treatment of cancer in solid organ transplant recipients.

Everolimus in de novo cardiac transplant recipients: 48-month (M) follow-up

2005 ◽  
Vol 24 (2) ◽  
pp. S61
Author(s):  
J.M. Hare ◽  
S. Perrone ◽  
H. Eisen ◽  
K. McCurry ◽  
P. Hauptman ◽  
...  
Keyword(s):  
De Novo ◽  
Cardiac Transplant ◽  
Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document